[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100179308":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":35,"responsibleParty":50,"collaborators":53,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":20,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":20,"studyType":69,"phases":70,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"University of Lausanne Hospitals","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-NODAGA-RGD radiotracer","EXPERIMENTAL","All patients will undergo a 68Ga-NODAGA-RGD PET\u002FCT, a 18F-FDG PET\u002FCT, a MRI and a US.",[13],"Drug: 68Ga-NODAGA-RGD PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","68Ga-NODAGA-RGD PET\u002FCT","200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired",[9],null,[22],{"name":23,"affiliation":24,"role":25},"John O. Prior, PhD, MD","Lausanne University Hospitals","PRINCIPAL_INVESTIGATOR",[27,31],{"name":23,"role":28,"phone":29,"phoneExt":20,"email":30},"CONTACT","+41 21 314 43 48","john.prior@chuv.ch",{"name":32,"role":28,"phone":33,"phoneExt":20,"email":34},"Emmanuel Deshayes, MD","+41 21 314 02 20","emmanuel.deshayes@chuv.ch",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":20},"Centre Hospitalier Universitaire Vaudois","RECRUITING","Lausanne","Canton of Vaud","1011","Switzerland","CH",{"type":45,"coordinates":46},"Point",[47,48],6.63282,46.516,{"lat":48,"lon":47},{"type":25,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"John O. Prior","Chief of Department of Nuclear Medicine",[54],{"name":55,"class":6},"Swiss Heart Foundation","100179308","phase-1-multimodal-imaging-assessment-of-the-inflammatory-atheromatous-plaque-100179308",false,"NCT01608516","Multimodal Imaging Assessment of the Inflammatory Atheromatous Plaque","Multimodal Assessment of the Inflammatory Atheromatous Plaque : Comparison Between 68Ga-NODAGA-RGD PET\u002FCT, 18F-FDG PET\u002FCT, MRI AND US","Inclusion Criteria:\n\n* age \\\u003C= 85 years\n* Karnofsky \\>= 80%\n* patient with indication ofr carotid endarterectomy\n* signed consent form\n\nExclusion Criteria:\n\n* indication for surgery other than endarterectomy \\\u003C14 days\n* contraindication to surgery\n* contraindication to MRI\n* contraindication to gadolinium injection (stage 4\u002F5 kidney insufficiency, GFR\\\u003C30ml\u002Fmin\u002F1.73m2)\n* pregnancy, breastfeeding\n* lack of discernment","ALL","18 Years","85 Years",{"count":67,"type":68},20,"ESTIMATED","INTERVENTIONAL",[71,72],"PHASE1","PHASE2","The present study aims at assessing the ability of 68Ga-NODAGA-RGD PET\u002FCT for the detection of inflammatory atheromatous plaques in the carotid arteries, compared to 18F-FDG PET\u002FCT, MRI and US and to determine the contribution of each imaging technique. Current gold standard for inflammation is histopathology.\n\nHypothesis : 68Ga-NODAGA-RGD might give a better initial evaluation of patients with atheromatous plaques in the carotid artery eligible for endarterectomy.",[75,76,77],"Inflammation","Atheromatous Plaques","Carotid Artery Diseases",[79,80,81,82,83,84,85],"PET\u002FCT","68Ga-NODAGA-RGD","18F-FDG","MRI","US ultrasound","inflammatory atheromatous plaque","endarterectomy","2024-06-17",{"date":88,"type":89},"2024-06-20","ACTUAL",{"date":91,"type":89},"2012-04",{"date":93,"type":68},"2024-12",{"name":5,"class":6},1]